Updated on 29 May 2012
The primary endpoint in the trial is a demonstration of a reduction in exacerbations requiring oral corticosteroid treatment or hospitalisation.
The secondary endpoints seek to determine if HI-164OV can reduce the severity of exacerbations, the number of patients experiencing exacerbations requiring corticosteroid treatment or hospitalisation and a reduction in the use of antibiotics and or corticosteroids. There have been no indications of patient-related safety issues during the trial.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
